{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:47:56Z","timestamp":1782175676885,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Kaohsiung Veteran General Hospital","award":["VGHKS109-043"],"award-info":[{"award-number":["VGHKS109-043"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00228-023-03491-7","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T15:02:11Z","timestamp":1681570931000},"page":"789-800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Risk factors for acute kidney injury after high-dose methotrexate therapy: a single-center study and narrative review"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1969-3295","authenticated-orcid":false,"given":"Chun-An","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyh-Jer","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"3491_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM194806032382301","volume":"238","author":"S Faber","year":"1948","unstructured":"Faber S, Diamond LK (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 238:787\u2013793. https:\/\/doi.org\/10.1056\/NEJM194806032382301","journal-title":"N Engl J Med"},{"key":"3491_CR2","doi-asserted-by":"publisher","first-page":"13481","DOI":"10.1073\/pnas.172501499","volume":"99","author":"PTR Rajagopalan","year":"2002","unstructured":"Rajagopalan PTR, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG (2002) Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics. Proc Natl Acad Sci USA 99:13481\u201313486. https:\/\/doi.org\/10.1073\/pnas.172501499","journal-title":"Proc Natl Acad Sci USA"},{"key":"3491_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","volume":"11","author":"BC Widemann","year":"2006","unstructured":"Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694\u2013703. https:\/\/doi.org\/10.1634\/theoncologist.11-6-694","journal-title":"Oncologist"},{"key":"3491_CR4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21:1471\u20131482. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"issue":"4","key":"3491_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/10600280221113092","volume":"57","author":"EG Boyce","year":"2023","unstructured":"Boyce EG, Rogan EL, Lui MC (2023) Upadacitinib for the treatment of rheumatoid arthritis: An extensive review. Ann Pharmacother 57(4):450\u2013462. https:\/\/doi.org\/10.1177\/10600280221113092","journal-title":"Ann Pharmacother"},{"key":"3491_CR6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","volume":"32","author":"SJ Strauss","year":"2021","unstructured":"Strauss SJ, Frezza AM, Abecassis N et al (2021) Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 32:1520\u20131536. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1995","journal-title":"Ann Oncol"},{"key":"3491_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1365-2125.2011.04054.x","volume":"73","author":"L Holmboe","year":"2012","unstructured":"Holmboe L, Andersen AM, M\u00f8rkrid L, Sl\u00f8rdal L, Hall KS (2012) High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 73:106\u2013114. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04054.x","journal-title":"Br J Clin Pharmacol"},{"key":"3491_CR8","doi-asserted-by":"publisher","unstructured":"Cheng DH, Lu H, Liu TT, Zou XQ, Pang HM (2018) Identification of risk factors in high-dose methotrexate-induced acute kidney injury in childhood acute lymphoblastic leukemia. Chemotherapy 63:101\u2013107. https:\/\/doi.org\/10.1159\/000486823","DOI":"10.1159\/000486823"},{"key":"3491_CR9","unstructured":"Hospira. Methotrexate injection, USP. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/011719s117lbl.pdf. Accessed 17 Mar\u00a02022"},{"key":"3491_CR10","doi-asserted-by":"publisher","unstructured":"May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND (2014) High incidence of methotrexate associated renal toxicity in patients with lymphoma: A retrospective analysis. Leuk Lymphoma 55:1345\u20131349.\u00a0https:\/\/doi.org\/10.3109\/10428194.2013.840780","DOI":"10.3109\/10428194.2013.840780"},{"key":"3491_CR11","doi-asserted-by":"publisher","unstructured":"Barreto JN, Peterson KT, Barreto EF et al (2021) Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. Support Care Cancer 29:5293\u20135301. https:\/\/doi.org\/10.1007\/s00520-021-06106-y","DOI":"10.1007\/s00520-021-06106-y"},{"key":"3491_CR12","doi-asserted-by":"publisher","unstructured":"Kawaguchi S, Fujiwara SI, Murahashi R et al (2021) Risk factors for high-dose methotrexate-induced nephrotoxicity. Int J Hematol 114:79\u201384. https:\/\/doi.org\/10.1007\/s12185-021-03132-8","DOI":"10.1007\/s12185-021-03132-8"},{"key":"3491_CR13","doi-asserted-by":"publisher","unstructured":"Yanagimachi M, Goto H, Kaneko T et al (2013) Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. Int J Hematol 98:702\u2013707. https:\/\/doi.org\/10.1007\/s12185-013-1464-z","DOI":"10.1007\/s12185-013-1464-z"},{"key":"3491_CR14","doi-asserted-by":"publisher","unstructured":"Widemann BC, Balis FM, Kim A et al (2010) Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: Clinical and pharmacologic factors affecting outcome. J Clin Oncol 28:3979\u20133986. https:\/\/doi.org\/10.1200\/jco.2009.25.4540","DOI":"10.1200\/jco.2009.25.4540"},{"key":"3491_CR15","doi-asserted-by":"publisher","unstructured":"Wiczer T, Dotson E, Tuten A, Phillips G, Maddocks K (2016) Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract 22:430\u2013436. https:\/\/doi.org\/10.1177\/1078155215594417","DOI":"10.1177\/1078155215594417"},{"key":"3491_CR16","doi-asserted-by":"publisher","unstructured":"Huang C, Xia F, Xue L et al (2020) Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1\/OAT3. Cancer Chemother Pharmacol 85:433\u2013441. https:\/\/doi.org\/10.1007\/s00280-019-03972-6","DOI":"10.1007\/s00280-019-03972-6"},{"key":"3491_CR17","unstructured":"Methotrexate. In: In Depth Answers [Interaction Checking]. Greenwood Village (CO): IBM Corporation; 2017 [cited 2022 Sep 22]. Available from: www.micromedexsolutions.com. Subscription required to view"},{"key":"3491_CR18","doi-asserted-by":"publisher","unstructured":"Bleyer WA (1977) Methotrexate: Clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4:87\u2013101. https:\/\/doi.org\/10.1016\/s0305-7372(77)80007-8","DOI":"10.1016\/s0305-7372(77)80007-8"},{"key":"3491_CR19","doi-asserted-by":"publisher","unstructured":"Schwartz GJ, Gauthier B (1985) A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 106:522\u2013526. https:\/\/doi.org\/10.1016\/s0022-3476(85)80697-1","DOI":"10.1016\/s0022-3476(85)80697-1"},{"key":"3491_CR20","doi-asserted-by":"publisher","unstructured":"Inker LA, Eneanya ND, Coresh J et al (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385:1737\u20131749. https:\/\/doi.org\/10.1056\/NEJMoa2102953","DOI":"10.1056\/NEJMoa2102953"},{"key":"3491_CR21","doi-asserted-by":"publisher","unstructured":"Medrano C, Oberic L, Puisset F et al (2021) Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: A cohort study of 468 patients. Leuk Lymphoma 62:846\u2013853. https:\/\/doi.org\/10.1080\/10428194.2020.1846733","DOI":"10.1080\/10428194.2020.1846733"},{"key":"3491_CR22","doi-asserted-by":"publisher","unstructured":"Wang Y, Wei L, Guan Y, Wang Q, Xie Q, Hao C (2020) Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients. Ren Fail 42:1111\u20131117. https:\/\/doi.org\/10.1080\/0886022X.2020.1838926","DOI":"10.1080\/0886022X.2020.1838926"},{"key":"3491_CR23","doi-asserted-by":"publisher","unstructured":"Amitai I, Rozovski U, El-Saleh R et al (2020) Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol 38:584\u2013588. https:\/\/doi.org\/10.1002\/hon.2759","DOI":"10.1002\/hon.2759"},{"key":"3491_CR24","doi-asserted-by":"publisher","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179\u2013184. https:\/\/doi.org\/10.1159\/000339789","DOI":"10.1159\/000339789"},{"key":"3491_CR25","unstructured":"Cancer Therapy Evaluation Program (CTEP). Common terminology criteria for adverse events (CTCAE). National Institutes of Health. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 17 Mar 2022"},{"key":"3491_CR26","doi-asserted-by":"publisher","unstructured":"Ackland SP, Schilsky RL (1987) High-dose methotrexate: A critical reappraisal. J Clin Oncol 5:2017\u20132031. https:\/\/doi.org\/10.1200\/jco.1987.5.12.2017","DOI":"10.1200\/jco.1987.5.12.2017"},{"key":"3491_CR27","doi-asserted-by":"publisher","unstructured":"Sasaki K, Tanaka J, Murakami T, Matuoka H, Fujimoto T, Taguchi H (1985) Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. Cancer Drug Deliv 2:77\u201386. https:\/\/doi.org\/10.1089\/cdd.1985.2.77","DOI":"10.1089\/cdd.1985.2.77"},{"key":"3491_CR28","doi-asserted-by":"publisher","unstructured":"de Miguel D, Garc\u00eda-Su\u00e1rez J, Mart\u00edn Y, Gil-Fern\u00e1ndez JJ, Burgaleta C (2008) Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: A significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant 23:3762\u20133766. https:\/\/doi.org\/10.1093\/ndt\/gfn503","DOI":"10.1093\/ndt\/gfn503"},{"key":"3491_CR29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1177\/1078155220953878","volume":"27","author":"I Kr\u00e4mer","year":"2021","unstructured":"Kr\u00e4mer I, Rosentreter J, Fried M, K\u00fchn M (2021) Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient. J Oncol Pharm Pract 27:1000\u20131004. https:\/\/doi.org\/10.1177\/1078155220953878","journal-title":"J Oncol Pharm Pract"},{"key":"3491_CR30","doi-asserted-by":"publisher","unstructured":"Yang Y, Wang X, Tian J, Wang Z (2018) Renal function and plasma methotrexate concentrations predict toxicities in adults receiving high-dose methotrexate. Med Sci Monit 24:7719\u20137726. https:\/\/doi.org\/10.12659\/MSM.912999","DOI":"10.12659\/MSM.912999"},{"key":"3491_CR31","doi-asserted-by":"publisher","unstructured":"Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J (2012) Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist 17:550\u2013554. https:\/\/doi.org\/10.1634\/theoncologist.2011-0431","DOI":"10.1634\/theoncologist.2011-0431"},{"key":"3491_CR32","doi-asserted-by":"publisher","unstructured":"Wang X, Song Y, Wang J et al (2020) Effect of proton pump inhibitors on high-dose methotrexate elimination: A systematic review and meta-analysis. Int J Clin Pharm 42:23\u201330. https:\/\/doi.org\/10.1007\/s11096-019-00958-5","DOI":"10.1007\/s11096-019-00958-5"},{"key":"3491_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3109\/0886022X.2014.917560","volume":"36","author":"X Wu","year":"2014","unstructured":"Wu X, Zhang W, Ren H, Chen X, Xie J, Chen N (2014) Diuretics associated acute kidney injury: Clinical and pathological analysis. Ren Fail 36:1051\u20131055. https:\/\/doi.org\/10.3109\/0886022X.2014.917560","journal-title":"Ren Fail"},{"key":"3491_CR34","doi-asserted-by":"publisher","first-page":"F146","DOI":"10.1152\/ajprenal.00154.2015","volume":"309","author":"PIA de Bruijn","year":"2015","unstructured":"de Bruijn PIA, Larsen CK, Frische S et al (2015) Furosemide-induced urinary acidification is caused by pronounced H+ secretion in the thick ascending limb. Am J Physiol Renal Physiol 309:F146-153. https:\/\/doi.org\/10.1152\/ajprenal.00154.2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"3491_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13613-016-0168-y","volume":"6","author":"L Zazzeron","year":"2016","unstructured":"Zazzeron L, Ottolina D, Scotti E et al (2016) Real-time urinary electrolyte monitoring after furosemide administration in surgical ICU patients with normal renal function. Ann Intensive Care 6:72. https:\/\/doi.org\/10.1186\/s13613-016-0168-y","journal-title":"Ann Intensive Care"},{"key":"3491_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-84843-3","volume-title":"Clinical nephrotoxins: Renal injury from drugs and chemicals","author":"M de Broe","year":"2008","unstructured":"de Broe M, Porter G, Bennett W, Deray G (2008) Clinical nephrotoxins: Renal injury from drugs and chemicals, 3rd edn. Springer, New York. https:\/\/doi.org\/10.1007\/978-0-387-84843-3","edition":"3"},{"key":"3491_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/SPC.0000000000000209","volume":"10","author":"R van Eeden","year":"2016","unstructured":"van Eeden R, Rapoport BL (2016) Current trends in the management of anaemia in solid tumours and haematological malignancies. Curr Opin Support Palliat Care 10:189\u2013194. https:\/\/doi.org\/10.1097\/SPC.0000000000000209","journal-title":"Curr Opin Support Palliat Care"},{"key":"3491_CR38","first-page":"151","volume":"42","author":"L Skibi\u0144ska","year":"1990","unstructured":"Skibi\u0144ska L, Ramlau C, Za\u0142uski J, Olejniczak B (1990) Methotrexate binding to human plasma proteins. Pol J Pharmacol Pharm 42:151\u2013157","journal-title":"Pol J Pharmacol Pharm"},{"issue":"10","key":"3491_CR39","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1177\/1060028021992767","volume":"55","author":"T Kataoka","year":"2021","unstructured":"Kataoka T, Sakurashita H, Kajikawa K, Saeki Y, Taogoshi T, Matsuo H (2021) Low serum albumin level is a risk factor for delayed methotrexate elimination in high-dose methotrexate treatment. Ann Pharmacother 55(10):1195\u20131202. https:\/\/doi.org\/10.1177\/1060028021992767","journal-title":"Ann Pharmacother"},{"key":"3491_CR40","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12185-020-03071-w","volume":"113","author":"T Nakano","year":"2021","unstructured":"Nakano T, Kobayashi R, Matsushima S et al (2021) Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma. Int J Hematol 113:744\u2013750. https:\/\/doi.org\/10.1007\/s12185-020-03071-w","journal-title":"Int J Hematol"},{"key":"3491_CR41","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3390\/cancers13112837","volume":"13","author":"ZL Taylor","year":"2021","unstructured":"Taylor ZL, Vang J, Lopez-Lopez E et al (2021) Systematic review of pharmacogenetic factors that influence high-dose methotrexate pharmacokinetics in pediatric malignancies. Cancers (Basel) 13:2837. https:\/\/doi.org\/10.3390\/cancers13112837","journal-title":"Cancers (Basel)"},{"key":"3491_CR42","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","volume":"121","author":"LB Ramsey","year":"2013","unstructured":"Ramsey LB, Panetta JC, Smith C et al (2013) Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121:898\u2013904. https:\/\/doi.org\/10.1182\/blood-2012-08-452839","journal-title":"Blood"},{"key":"3491_CR43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","volume":"78","author":"RH Ho","year":"2005","unstructured":"Ho RH, Kim RB (2005) Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther 78:260\u2013277. https:\/\/doi.org\/10.1016\/j.clpt.2005.05.011","journal-title":"Clin Pharmacol Ther"},{"key":"3491_CR44","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/pbc.23074","volume":"57","author":"E Lopez-Lopez","year":"2011","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J et al (2011) Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:612\u2013619. https:\/\/doi.org\/10.1002\/pbc.23074","journal-title":"Pediatr Blood Cancer"},{"key":"3491_CR45","first-page":"6109","volume":"8","author":"Li j, Wang X, Zhai X,","year":"2015","unstructured":"Li j, Wang X, Zhai X et al (2015) Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia. Int J Clin Exp Med 8:6109\u20136113","journal-title":"Int J Clin Exp Med"},{"key":"3491_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey LB, Balis FM, O\u2019Brien MM et al (2018) Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 23:52\u201361. https:\/\/doi.org\/10.1634\/theoncologist.2017-0243","journal-title":"Oncologist"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03491-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03491-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03491-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:12:24Z","timestamp":1685434344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03491-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3491"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03491-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"1 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Institutional Board Review of Kaohsiung Veterans General Hospital (20-CT3-17).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was exempted from the requirement of informed patient consent due to its retrospective nature and epidemiological design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}}]}}